A new biotech company, Callio Therapeutics, has been launched with the goal of developing multi-payload antibody-drug conjugates (ADCs), an approach it and several other companies are exploring to boost the technology’s efficacy.
Headquartered in Seattle and Singapore, Callio has been created by venture capital firm Frazier Life Sciences, which last week led a consortium in a $187m series A financing, based on...
Key Takeaways
- The dual-payload approach aims to block the resistance mechanism seen with Enhertu.
- Callio joins a handful of other currently preclinical companies pioneering...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?